Estia Health (ASX:EHE) share price dips on class action settlement

The Estia Health (ASX: EHE) share price dipped and then recovered today after news it has received approval to settle a class action lawsuit.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Estia Health Ltd (ASX: EHE) received Federal Court approval this afternoon to settle a class action brought against it.

The Estia Health share price dipped sharply immediately after the news was announced to the ASX, but has since returned to its prior trading level of $2.50, up 2%.

Estia Health is one of Australia's largest residential aged care providers delivering care to more than 8,000 older Australians each year.

Let's have a closer look at the settlement and class action brought against the company.

2 professionals shaking hands

Class action

The class action against Estia has been ongoing since July 2019. Filed to the Federal Court by law firm Phi Finney McDonald, it relates to alleged breaches of the company's disclosure obligations in 2015 and 2016.

The lawsuit concerned shareholders who had bought shares in the company or acquired long exposure to Estia shares by entering into equity swap confirmations between August 2016 and October 2016.

At the time, the Australian Financial Review reported the class action alleged Estia didn't disclose difficulties it was experiencing around the time it published its 2016 financial year results. It also alleged the company gave misleading guidance for the 2017 financial year. 

In February 2021, Estia advised the market it had reached an agreement to settle the class action, conditional on whether the settlement would receive Federal Court approval.

Today, Estia said that the cost of the settlement is $38.5 million, of which it has contributed $12.35 million. The remaining balance is to be paid by Estia's insurers.

Estia Health share price snapshot

The Estia Health share price has been a strong performer on the ASX lately. Currently, it's up 41% year to date and has lifted 72% over the last 12 months.

The company has a market capitalisation of around $640 million, with approximately 261 million shares outstanding.

More on Healthcare Shares

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »